News
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Chemed Corporation to Present at the BofA Securities 2023 Virtual Home Care Conference
Chemed Corporation (NYSE:CHE) today announced that it will present at the BofA Securities 2023 Virtual Home Care Conference on Monday, December 4, 2023, at 2:10 PM (ET).
The presentation will be
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration
Charles River Laboratories International, Inc. (NYSE: CRL) and Genetic Cures for Kids Inc (GC4K), an Australian non-profit foundation focused on research programs and clinical trials to find cures
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
Novocure (NASDAQ: NVCR) today announced a series of actions to strengthen and optimize business operations to support near-term growth drivers and long-term value creation. The plan includes an
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Charles River Laboratories to Present at Evercore ISI Investor Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29th, at 9:10 a.m. ET
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today
Premier, Inc. to Participate in Piper Sandler Healthcare Conference on November 29, 2023
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in a fireside chat at the Piper
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that management will participate in the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023. William Doyle, Novocure’s Executive
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
First half results 2023/24: Substantial acceleration in sales growth expected as temporary headwinds subside
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, announced today that the European Commission (EC) has approved EBGLYSS (lebrikizumab) for the treatment
Gilbert Achermann to be nominated as a new member of the Sonova Board of Directors
Charles River Introduces CliniPrime Cryopreserved Leukopaks, Expanding Suite of GMP-Compliant Cellular Products
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its CliniPrime™ suite of Good Manufacturing Practice (GMP)-compliant offerings with the launch of
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Tufts Medicine Selects Premier, Inc. as Strategic Partner to Achieve Supply Chain Excellence
Premier, Inc. (NASDAQ: PINC), a leading technology-enabled performance improvement company, today announced a renewed partnership with Tufts Medicine, a leading integrated health system bringing
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced a drug